异烟肼预防性治疗与HIV感染孕妇妊娠结局的Tshepiso队列分析
该研究为Tshepiso前瞻性观察队列的二次分析,纳入南非索韦托2011-2014年151名HIV感染孕妇,评估妊娠期异烟肼预防性治疗(IPT)暴露与不良妊娠结局的关联。控制年龄、CD4、病毒载量等因素后,未暴露组不良结局调整OR为2.5(95%CI 1.0-6.5;
要点
- 妊娠期IPT暴露未增加不良妊娠结局风险。
- 结果支持妊娠中晚期可安全使用IPT。
核心结论
- 控制人口学、临床及HIV相关因素后,妊娠期IPT暴露与不良妊娠结局无负相关。
研究设计与样本
- Tshepiso前瞻性观察队列的二次分析,纳入南非索韦托2011-2014年151名已知妊娠结局的HIV感染孕妇。
主要发现
- 69名(46%)孕妇报告妊娠期启动IPT,其中11名(16%)出现不良妊娠结局。
- 未暴露IPT的孕妇中23名(28%)出现不良妊娠结局。
临床怎么用
- 结果提供一定 reassurance,IPT可在妊娠中晚期安全使用。
局限性
- 需进一步研究评估IPT及新型短程结核预防治疗在妊娠期的安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Both pregnancy and human immunodeficiency virus (HIV) increase the risk of tuberculosis disease, which results in poor maternal, pregnancy, and infant outcomes. Isoniazid preventive therapy (IPT) reduces mortality among individuals living with HIV in high-burden settings but has recently been associated with adverse pregnancy outcomes when initiated during pregnancy. METHODS: In this secondary analysis, we used multivariable logistic regression to evaluate the association between IPT exposure and adverse pregnancy outcomes (fetal demise, prematurity, low birth weight, congenital anomaly) in pregnant women living with HIV enrolled as controls in the Tshepiso study, a prospective observational cohort of pregnant women living with HIV with and without tuberculosis disease in Soweto, South Africa, from 2011-2014. RESULTS: There were 151 women enrolled with known pregnancy outcomes; 69 (46%) reported IPT initiation during pregnancy. Of the 69 IPT-exposed women, 11 (16%) had an adverse pregnancy outcome compared with 23 (28%) IPT-unexposed women. The adjusted odds of having an adverse pregnancy outcome was 2.5 (95% confidence interval, 1.0-6.5; P = .048) times higher in IPT-unexposed women compared with IPT-exposed women after controlling for maternal age, CD4 count, viral load, antiretroviral regimen, body mass index, and anemia. CONCLUSIONS: IPT exposure during pregnancy was not negatively associated with pregnancy outcomes after controlling for demographic, clinical, and HIV-related factors. These results provide some reassurance that IPT can be safely used in the second or third trimester of pregnancy. Additional research is needed to evaluate the safety of IPT and new short-course tuberculosis preventive therapies during pregnancy.
引用
- Salazar-Austin N, Cohn S, Lala S, et al. Isoniazid Preventive Therapy and Pregnancy Outcomes in Women Living With Human Immunodeficiency Virus in the Tshepiso Cohort. Clin Infect Dis. 2020. PMID: 31631221. doi:10.1093/cid/ciz1024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。